Treatment of retinal detachment in people who have not had cataract surgery and are not very short-sighted with either vitrectomy surgery alone or with vitrectomy and removal of the cataract at the same time

| Submission date | Recruitment status | [X] Prospectively registered |
|-------------------|----------------------|---------------------------------|
| 11/04/2025 | Recruiting | ☐ Protocol |
| Registration date | Overall study status | Statistical analysis plan |
| 17/04/2025 | Ongoing | ☐ Results |
| Last Edited | Condition category | ☐ Individual participant data |
| 08/05/2025 | Eye Diseases | [X] Record updated in last year |

Plain English summary of protocol

Background and study aims

The retina is the layer at the back of the eye that allows us to see. Sometimes, it can detach from the wall of the eye, causing a condition called rhegmatogenous retinal detachment (RRD), which leads to vision loss and requires surgery. The most common surgery for RRD is vitrectomy, but this can lead to complications like cataracts, which worsen over time and need to be removed with another surgery. Cataract surgery involves replacing the cloudy lens with a clear artificial one. Currently, it's unclear whether it's better to perform both surgeries at the same time or separately. The COMBAT study aims to find out which approach is best by comparing the outcomes of patients who have vitrectomy alone versus those who have both surgeries together.

Who can participate?

Adults aged 50 and older who have RRD but are not highly myopic (less than -6 diopters or an axial length of 26.5 mm or less) and have not had previous vitreoretinal surgery. Participants must be scheduled for a pars plana vitrectomy to repair their RRD.

What does the study involve?

Participants will be randomly assigned to one of two groups: one group will have vitrectomy first and, if needed, cataract surgery later; the other group will have both surgeries at the same time. The study will compare their vision, the number of successful retina reattachments, patient satisfaction, complications, and costs.

What are the possible benefits and risks of participating?

The possible benefits include improved vision and a better understanding of the best surgical approach for RRD. However, there are risks associated with any surgery, including complications from vitrectomy and cataract surgery.

Where is the study run from? Queen's University Belfast (UK)

When is the study starting and how long is it expected to run for? November 2024 to October 2028.

Who is funding the study? Queen's University Belfast (UK)

Who is the main contact? Colette Jackson, Trial Manager, colette.jackson@nictu.hscni.net Professor Noemi Lois, Chief Investigator, at n.lois@qub.ac.uk

Contact information

Type(s)

Public

Contact name

Ms Colette Jackson

ORCID ID

https://orcid.org/0000-0001-7814-0749

Contact details

Northern Ireland Clinical Trials Unit 7 Lennoxvale Belfast United Kingdom **BT9 5BY**

colette.jackson@nictu.hscni.net

Type(s)

Scientific, Principal investigator

Contact name

Prof Noemi Lois

ORCID ID

https://orcid.org/0000-0003-2666-2937

Contact details

The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road **Belfast**

United Kingdom

BT9 7BL

n.lois@qub.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

338079

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 60043

Study information

Scientific Title

COMBAT: Clinical- and cost-effectiveness, safety and acceptability of COMBined phacovitrectomy, versus sequentiAl viTrectomy and cataract surgery, for the management of rhegmatogenous retinal detachment: A Randomised Equivalence Clinical Trial

Acronym

COMBAT

Study objectives

Aim

To determine whether, in people with non-highly myopic phakic rhegmatogenous retinal detachment (RRD) (Population), phacovitrectomy (Intervention) is equivalent (equivalence margin +/- 7 Early Treatment Diabetic Retinopathy Study ETDRS letters) to vitrectomy and subsequent cataract surgery (phacoemulsification) if/when needed (Comparator) for improving vision following surgery (primary Outcome) but superior for other (secondary) outcomes (as listed in this protocol) in the 52 weeks (+/- 6 weeks) after surgery.

Objectives

To determine if, in people presenting with non-highly myopic phakic RRD, phacovitrectomy (i.e. removing the cataract and doing vitrectomy to repair the RRD) is as good or better as doing only the retinal detachment repair with vitrectomy and then, if and when the cataract develops, doing a phaco (i.e. cataract surgery) and to assess post-trial implementation strategies and scalability.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 25/03/2025, Yorkshire & The Humber - Leeds West Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle-upon-Tyne, NE2 4NQ, United Kingdom; +44 2071048100; leedswest.rec@hra.nhs.uk), ref: 25/YH/0056

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Rhegmatogenous retinal detachment

Interventions

Following consent, participants will be reviewed by the research team, including their surgeon. Previous medical and eye history will be reviewed, and measurements of the eye and baseline data (including 5 questionnaires) will then be collected. Patients will then be seen again at 1, 6, 12, and 52 weeks (+/- 6 weeks) post-surgery for the measurements and baseline data collection. Participation in the study will end following the 52-week visit.

Participants will also have the option at their initial study discussion to give consent to be contacted in the future to take part in individual interviews to talk about their opinions and experiences of treatment. The study PPI group gave favorable feedback about the proposed options for the consenting process (written/verbal) for interviews. Participants can receive an audio recording of their consent if they request this. A total of 3 (maximum) individual interviews will be undertaken by the participant.

Health care professionals will also be invited to give online consent to take part in an individual /small group discussion to share their views on the barriers and facilitators involved in the implementation of the COMBAT study.

Studies within a Trial (SWAT)

There will be 2 SWATs embedded in the trial:

SWAT A - Will record the proportion in each of the demographic groups who are recruited and retained at each site. We will also collect information over the course of the trial on how often the translated PIL are used and whether people for whom these are used are recruited and retained.

SWAT B - Sites who are willing to take part will evaluate whether an EDI-informed PIL increases the recruitment of underserved groups compared to the standard PIL. The exact content of the modified PIL is dependent on qualitative, diverse PPI work to be done during (around) the first year of the COMBAT study.

Timeline

The total study duration will be 48 months:

Months 1-6: Set up activities.

Months 7-15: Pilot Phase - Opening site, recruitment, data collection & follow-up, qualitative small discussions/interviews tasks.

Months 16-30: Main Study - Opening site, recruitment, data collection & follow-up, qualitative small discussions/interviews tasks.

Months 31-42: Follow-up, data cleaning, qualitative small discussions/interviews tasks.

Months 43-48: Write-up, reporting, and dissemination.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Change in Best-Corrected Visual Acuity (BCVA) in the study eye from baseline to 52 weeks (+/- 6 weeks) after surgery (equivalence margin +/- 7 ETDRS letters).

Key secondary outcome(s))

- 1. Primary anatomical success is measured using retinal attachment status at 52 weeks (+/- 6 weeks) after one vitrectomy
- 2. Final anatomical success is measured using retinal attachment status at 52 weeks (+/- 6 weeks) after two or more vitrectomies
- 3. Intraoperative complications are measured using severity score during surgery
- 4. Postoperative complications are measured using severity score at 52 weeks (+/- 6 weeks) after surgery
- 5. Number and type of surgeries performed are measured using surgical records at 52 weeks (+/- 6 weeks) after surgery
- 6. Refractive error is measured using the difference between aimed and obtained post-operative refraction at 12 weeks after surgery in the phaco-vitrectomy arm and 6-8 weeks post-cataract surgery in the vitrectomy only arm
- 7. Proportion of participants with BCVA <69 letters is measured using BCVA test at 52 weeks (+/-6 weeks) after surgery
- 8. Proportion of participants with BCVA <34 letters is measured using BCVA test at 52 weeks (+/- 6 weeks) after surgery
- 9. Time to achieve 'best vision' is measured using BCVA test at baseline and 52 weeks (+/- 6 weeks) after surgery
- 10. Change in BCVA from baseline over time is measured using BCVA test at baseline and 52 weeks (+/- 6 weeks) after surgery
- 11. Health-related quality of life is measured using EuroQol-5 level (EQ-5D-5L) at baseline and 52 weeks (+/- 6 weeks) after surgery
- 12. Vision-specific quality of life is measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) at baseline and 52 weeks (+/- 6 weeks) after surgery
- 13. Participant's experience and acceptability of treatments are measured using questionnaires at 52 weeks (+/- 6 weeks) after surgery
- 14. Use of health and social care services and non-health care is measured using questionnaires at 52 weeks (+/- 6 weeks) after surgery
- 15. Safety is measured using AE/SAE reporting at 52 weeks (+/- 6 weeks) after surgery

Completion date

31/10/2028

Eligibility

Key inclusion criteria

- 1. Adults ≥50 years of age
- 2. Non-highly myopic (< -6 diopters; ≤26.5 mm axial length) phakic RRD
- 3. Naïve to previous vitreoretinal surgery
- 4. Pars plana vitrectomy is planned to repair their RRD

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

50 years

Sex

All

Key exclusion criteria

1. Presence of a "formed/established cataract." A "formed/established cataract" is defined as a cataract that, based on the Age-Related Eye Disease Study (AREDS)

Research Group, is graded as nuclear sclerosis of >3 and/or if there is an anterior cortical cataract and/or a

subcapsular posterior cataract involving the visual axis.

- 2. Pseudophakia or aphakia.
- 3. High myopia (≥ -6 diopters; >26.5 mm axial length).
- 4. Giant retinal tear (i.e. presence of one or more retinal tears of >3 clock hours in size)
- 5. Retinal dialysis
- 6. Inclusion in an investigational drug study
- 7. Declined consent for participation

Date of first enrolment

09/05/2025

Date of final enrolment

30/04/2027

Locations

Countries of recruitment

United Kingdom

England

Northern Ireland

Scotland

Study participating centre Belfast Health and Social Care Trust

Trust Headquarters A Floor - Belfast City Hospital Lisburn Road Belfast United Kingdom BT9 7AB

Study participating centre Barts Health NHS Trust

The Royal London Hospital 80 Newark Street London United Kingdom E1 2ES

Study participating centre Bradford Teaching Hospitals NHS Foundation Trust

Bradford Royal Infirmary Duckworth Lane Bradford United Kingdom BD9 6RJ

Study participating centre Guys and St Thomas' NHS Foundation Trust

249 Westminster Bridge Road London United Kingdom SE1 7EH

Study participating centre Kings College Hospital

Mapother House De Crespigny Park Denmark Hill London United Kingdom SE5 8AB

Study participating centre Liverpool University Hospitals NHS Foundation Trust

Royal Liverpool University Hospital Prescot Street Liverpool United Kingdom L7 8XP

Study participating centre Buckinghamshire Healthcare NHS Trust

Amersham Hospital Whielden Street Amersham United Kingdom HP7 0JD

Study participating centre County Durham and Darlington NHS Foundation Trust

Darlington Memorial Hospital Hollyhurst Road Darlington United Kingdom DL3 6HX

Study participating centre Hull University Teaching Hospitals NHS Trust

Hull Royal Infirmary Anlaby Road Hull United Kingdom HU3 2JZ

Study participating centre Manchester University NHS Foundation Trust

Cobbett House Oxford Road Manchester United Kingdom M13 9WL

Study participating centre Moorfields Eye Hospital NHS Foundation Trust

162 City Road London United Kingdom EC1V 2PD

Study participating centre Oxford University Hospitals NHS Foundation Trust

John Radcliffe Hospital Headley Way Headington Oxford United Kingdom OX3 9DU

Study participating centre Sandwell and West Birmingham Hospitals NHS Trust

City Hospital Dudley Road Birmingham United Kingdom B18 7QH

Study participating centre Sheffield Teaching Hospitals NHS Foundation Trust

Northern General Hospital Herries Road Sheffield United Kingdom S5 7AU

Study participating centre South Tees Hospitals NHS Foundation Trust

James Cook University Hospital Marton Road Middlesbrough United Kingdom TS4 3BW

Study participating centre South Tyneside and Sunderland NHS Foundation Trust

Sunderland Royal Hospital Kayll Road Sunderland United Kingdom SR4 7TP

Study participating centre Leeds Teaching Hospitals NHS Trust

St. James's University Hospital Beckett Street Leeds United Kingdom LS9 7TF

Study participating centre

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Freeman Hospital Freeman Road High Heaton Newcastle upon Tyne United Kingdom NE7 7DN

Study participating centre The Royal Wolverhampton NHS Trust

New Cross Hospital Wolverhampton Road Heath Town Wolverhampton United Kingdom WV10 0QP

Study participating centre

University Hospital Southampton NHS Foundation Trust

Southampton General Hospital Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre

University Hospitals Bristol and Weston NHS Foundation Trust

Trust Headquarters Marlborough Street Bristol United Kingdom BS1 3NU

Study participating centre University Hospitals Dorset NHS Foundation Trust

Management Offices Poole Hospital Longfleet Road Poole United Kingdom BH15 2JB

Study participating centre University Hospitals of Leicester NHS Trust

Leicester Royal Infirmary Infirmary Square Leicester United Kingdom LE1 5WW

Study participating centre University Hospitals Sussex NHS Foundation Trust

Worthing Hospital Lyndhurst Road Worthing United Kingdom BN11 2DH

Study participating centre

York and Scarborough Teaching Hospitals NHS Foundation Trust

York Hospital Wigginton Road York United Kingdom YO31 8HE

Study participating centre University Hospitals Plymouth NHS Trust

Derriford Hospital Derriford Road Derriford Plymouth United Kingdom PL6 8DH

Study participating centre Mid and South Essex NHS Foundation Trust

Prittlewell Chase Westcliff-on-sea United Kingdom SSO ORY

Study participating centre NHS Greater Glasgow and Clyde

J B Russell House Gartnavel Royal Hospital 1055 Great Western Road Glasgow Glasgow United Kingdom G12 0XH

Study participating centre Queen's University Belfast

Centre for Public Health Belfast United Kingdom BT7 1NN

Study participating centre Royal Berkshire NHS Foundation Trust

Royal Berkshire Hospital London Road Reading United Kingdom RG1 5AN

Sponsor information

Organisation

Queen's University Belfast

ROR

https://ror.org/00hswnk62

Funder(s)

Funder type

University/education

Funder Name

Queen's University Belfast

Alternative Name(s)

QUB

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Following publication of the primary and secondary outcomes and after data has been fully exploited by the COMBAT research team, there may be scope to conduct additional analyses on the data collected. In such instances, formal requests for data will need to be made in writing to the CI via the NICTU. If there are requests for data sharing, these will be reviewed on a case-bycase basis by the CI and NICTU (Northern Ireland Clinical Trials Unit, 7 Lennoxvale, Belfast) with approval by the Sponsor required before data are shared.

IPD sharing plan summary

Available on request

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant

Participant information sheet 11/11/2025 11/11/2025 No

Yes